COPENHAGEN--(BUSINESS WIRE)--Unprecedented sustained viral response (SVR) rates were achieved in hepatitis C-infected treatment-failure patients, including those with cirrhosis, with telaprevir-based treatment according to PROVE 3 trial results presented today in the late breaker session at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. Telaprevir is being developed by Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) in collaboration with Tibotec and Mitsubishi Tanabe Pharma.
